Show
Sort by
-
- Journal Article
- A1
- open access
Dupilumab in CRSwNP : responder analysis using clinically meaningful efficacy outcome thresholds
-
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP
-
Dupilumab improves health‐related quality of life in patients with chronic rhinosinusitis with nasal polyposis
-
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD
-
- Journal Article
- A1
- open access
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
-
Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps : results from the randomized phase 3 sinus-24 study
-
- Conference Paper
- C3
- open access
A randomized phase 3 study, SINUS-52, evaluating the efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps
-
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52) : results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
-
Atopic comorbidities and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) who failed intranasal corticosteroids
-
Dupilumab improves sense of smell and reduces anosmia among patients with nasal polyposis and chronic sinusitis : results from a phase 2a trial